LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce the filing of additional patents with the United States Patent and Trade Office (USPTO) which it believes further protects the Company's innovations in the commercialization of a broad array of functional mushroom ingredients for the rapidly growing consumer and enterprise markets.
The three additional patents that have been filed are as follows:
Mushroom Accelerator System for Mycelium Cultivation - This patent focuses on a general mushroom accelerator setup utilizing AI and machine learning to regulate mycelium growth conditions such as temperature, oxygenation, and nutrient levels. It emphasizes cloud-based monitoring and user control via a mobile application.
Commercial Mushroom Accelerator System - This patent is designed for large-scale, high-yield production of mycelium and features modular cartridges, an integrated agitation system, and AI-driven automation. It is more suited for commercial applications rather than small-scale cultivation.
Replaceable Sterile Cartridge System - This patent introduces a specialized cartridge system that can be easily replaced within the Mushroom Accelerator, improving sterility and convenience. It leverages AI and machine learning to optimize growth and extraction processes, with a strong emphasis on maintaining consistent, medicinal-grade output.
"We are blazing an innovative trail, harnessing the magic of the mushroom and bringing it everywhere from the comfort of the home to commercial kitchens who want predictable, scalable mushroom ingredients in their offering," stated Stone Douglass, CEO, Hypha Labs. "These patents, which we have briefly detailed herein, affirm our strong position in the space as we look to our product roll-out on the not-so-far horizon, protecting our mass production plans, A.I. integrations, and maybe most importantly our Replaceable Sterile Cartridge System which to the keen eye should make clear our evergreen relationship with the customer vis-à-vis the razor/razor blade model fully in play."
Hypha Labs remains committed to advancing the science of mushroom cultivation equipment and genetic research to accommodate these advances. The integration of its new HPLC machine and the variable loop autosampler upgrade marks a significant milestone in Hypha's journey to deliver innovative solutions and insights to our customers, clients and partners.
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity MediaInc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/hypha-labs-files-multiple-additional-patents-for-its-ground-breaking-1026892
